Given that there is no benefit and potential harm in providing patients with immunosuppressive corticosteroids prior to oxygenation requirements in COVID-19 (9), an α2 AR agonist could potentially be used as an immunomodulator in the earlier stages of COVID-19—prior to requirement of oxygenation—where corticosteroids have been ineffective (9). The gene discussed is ADORA2A; the disease is COVID-19.